Point72 Hong Kong LTD Affimed N.V. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $19,249 - $32,605	9,821 Added 147.93%	16,460 $34,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $15,070 - $32,265	6,639 New	6,639 $18,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $80,806 - $109,540	-14,586 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $110,009 - $161,196	14,140 Added 3170.4%	14,586 $124,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $2,283 - $3,782	446 New	446 $4,000
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $4,714 - $9,887	-3,274 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $7,366 - $10,051	3,274 New	3,274 $9,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.